Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells.

ABSTRACT:

Background

Trastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive gastric cancer; however, trastuzumab resistance is a major problem in clinical practice. To comprehend the mechanism of trastuzumab resistance, we focused on the Wnt/β-catenin signaling pathway and its influence on the phenotypes and behavior of trastuzumab-resistant gastric cancer cells.

Methods

Trastuzumab-resistant NCI-N87R cells were established in vitro from the human gastric cancer cell line NCI-N87 by dose-escalating repeated trastuzumab treatment. We investigated the phenotypes of NCI-N87R cells, including Wnt signaling pathway activity. Gastric cancer organoid cells were incubated with complete medium and Wnt3a-depletion

SUBMITTER: Kim Y 

PROVIDER: S-EPMC10542239 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature